Delving into the Latest Updates on Grass pollen allergy immunotherapy(BIAL-Portela & Cia SA) with Synapse

Overview

Basic Info

Drug Type

Allergen extract

Synonyms

Allergenic extract, grass, timothy, Allergenic extract, timothy grass, Allergenic extract,timothy grass pollen

+ [22]

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Immune System DiseasesInfectious DiseasesEye Diseases+ [2]

Active Indication-

Inactive Indication

Allergic rhinoconjunctivitisConjunctivitis, AllergicRhinitis, Allergic, Seasonal

Originator Organization

BIAL-Portela & Cia SA

Active Organization-

Inactive Organization

ROXALL Medizin GmbH

BIAL-Portela & Cia SA

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Primary goal of this non-interventional study is to evaluate the change in level of allergen-specific IgE (EAST class) after allergen-specific immunotherapy with Pollinex Quattro with tree and/or grass pollen extracts and their mixtures under medial routine at adults with tree- and/or grass-medicated pollinosis.

Start Date22 Apr 2020

Sponsor / Collaborator

Allergy Therapeutics Plc

NCT02849210 / CompletedPhase 1

A Phase I Multicenter, Open Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea

The study was designed according to the draft of allergenic product regulation published by Spanish Regulatory Agency. The aim of the study is to evaluate the safety and tolerability of subcutaneous immunotherapy with Olea europaea pollen extract in patients with rhinoconjunctivitis with or without associated mild asthma. In addition, surrogate efficacy parameters will be evaluated: immunoglobulin level changes and skin reactivity

Start Date01 Sep 2015

Sponsor / Collaborator

ROXALL Medicina España S.A.

NCT02477917 / CompletedPhase 1

A Multicenter, Open Clinical Trial With Subcutaneous Immunotherapy in Depot in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica

The study was designed according to the draft of allergenic product regulation published by Spanish Regulatory Agency. The aim of the study is to evaluate the safety and tolerability of subcutaneous immunotherapy with Parietaria judaica pollen extract in patients with rhinoconjunctivitis with or without associated mild asthma. In addition, surrogate efficacy parameters will be evaluated: immunoglobulin level changes and skin reactivity.

Start Date01 May 2015

Sponsor / Collaborator

ROXALL Medicina España S.A.

100 Clinical Results associated with Grass pollen allergy immunotherapy(BIAL-Portela & Cia SA)

Login to view more data

100 Translational Medicine associated with Grass pollen allergy immunotherapy(BIAL-Portela & Cia SA)

Login to view more data

100 Patents (Medical) associated with Grass pollen allergy immunotherapy(BIAL-Portela & Cia SA)

Login to view more data

103

Literatures (Medical) associated with Grass pollen allergy immunotherapy(BIAL-Portela & Cia SA)

01 Dec 2021·Journal of Dairy ScienceQ1 · AGRICULTURAL & FORESTRY SCIENCE

Effects of oral administration of timothy hay and psyllium on the growth performance and fecal microbiota of preweaning calves

Q1 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Koike, S ; Hirano, K ; Maruyama, D ; Kodithuwakku, K A H T ; Owada, H ; Suzuki, Y ; Miura, H ; Kobayashi, Y

The objective of this study was to evaluate the effects of oral administration of fiber from the first week of life on the growth and hindgut environment of preweaning calves. Twenty newborn female Holstein calves were divided into 2 groups as control and treatment. Calves in both groups were reared under the same feeding program except for oral fiber administration. Timothy hay and psyllium were mixed at a 50-to-6 ratio as a treatment diet for oral fiber administration. Calves in the treatment group were orally administered 50 g of fiber daily from 3 to 7 d of age and 100 g of fiber from 8 d of age until weaning. Feed intake and occurrence of diarrhea were recorded daily, and body weight (BW) was recorded weekly for the individual calf. Fresh feces were collected from calves at 7, 21, 35, 49, and 56 d of age to analyze fermentation parameters and microbiota to characterize the hindgut environment. Higher fiber intake in the treatment group due to oral administration of timothy and psyllium did not affect the starter intake and achieved higher BW at 21 d of age. The fecal pH, total volatile fatty acid, lactate, and ammonia nitrogen concentrations were not affected by oral fiber administration; meanwhile, the molar proportion of propionate was higher in the treatment group at 7 d of age. The difference in fecal microbiota in the calves subjected to the oral administration of fiber was observed within 21 d of life; Lactobacillus spp. and Prevotella spp. showed higher abundance, whereas that of Clostridium perfringens was decreased. These higher abundances of beneficial bacteria and lower abundance of pathogenic bacteria during early life may partly explain the higher BW of calves in the treatment group at 21 d of age. Furthermore, no adverse effect was observed for the BW and health status in the treatment group throughout the preweaning period. Therefore, early fiber feeding via oral administration potentially contributes to improving the hindgut environment in newborn calves, which leads to better growth of calves during the early stage of life.

01 Mar 2021·World Allergy Organization JournalQ3 · MEDICINE

Proteomic profiling of commercial dust mite skin prick test solutions and allergy vaccines from India

Q3 · MEDICINE

ArticleOA

Author: Briza, Peter ; Bohle, Barbara ; Gadermaier, Gabriele ; Ferreira, Fatima ; Huber, Sara

BACKGROUNDSkin prick test (SPT) solutions and allergy vaccines (AVs) are crucial tools for diagnosis and therapy of allergies. It was the aim of this study to corroborate the content of products for diagnosis and treatment of dust mite allergies that are produced and sold in India.METHODSSDS-PAGE, immunoblots and high-resolution mass spectrometric analysis was performed with 16 house dust mite (HDM) SPT solutions and AVs from 3 Indian manufacturers. Authority-approved European SPT solutions and in-house extracts were used as references.RESULTSFrom the 5 Indian Dermatophagoides pteronyssinus products, none contained proteins from this source. Instead, 1 sample contained Dermatophagoides farinae and human serum proteins, 4 products contained allergens from the storage mite Suidasia medanensis, allergens from the legume Cicer arietinum (chickpea), and proteins from baker's yeast. From 4 Indian D. farinae-labeled products, 2 contained human serum proteins and a limited number of D. farinae allergens. Two contained only Suidasia, Cicer, and yeast proteins. In contrast, the European authority-approved D. pteronyssinus and D. farinae SPT solutions that were used as reference in this study, contained exclusively proteins of the respective species and covered the expected allergen spectra. The Blomia tropicalis sample contained no Blomia allergens at all, but consisted exclusively of Suidasia, Cicer, and yeast proteins. All 6 HDM samples consisted of human serum proteins and limited amounts of D. farinae allergens.CONCLUSIONSAll commercial Indian SPT solutions and AVs analyzed in this study are not suitable for dust mite allergy diagnosis and therapy, as they contain either no, or only a limited number of, HDM allergens. In addition, their use could lead to misdiagnosis since some of them contain allergens from other sources, including the storage mite Suidasia, chickpea, as well as baker's yeast. Further, their application might be harmful to patients, as some products contain large amounts of proteins of human origin. Analysis of European SPT solutions, on the other hand, confirmed their suitability for dust mite allergy diagnosis.

01 May 2020·Iranian journal of basic medical sciencesQ4 · MEDICINE

Incorporation of T-cell epitopes from tetanus and diphtheria toxoids into in-silico-designed hypoallergenic vaccine may enhance the protective immune response against allergens.

Q4 · MEDICINE

ArticleOA

Author: Mohammadi, Mohsen ; Jafary, Mojtaba ; Assarezadegan, Mohamad-Ali ; Ghasemi, Ali ; Falak, Reza ; June Maleki, Soheila

OBJECTIVESNew generation of allergy vaccines is capable of promoting the development of protective IgG and blocking the functionality of allergen-specific IgE. We incorporated universal and powerful T-cell epitopes from tetanus and diphtheria toxoids (TD epitope) into recombinant Che a 2, the well-known allergic profilin of Chenopodium album, to determine its immunological properties.MATERIALS AND METHODSThe sequence and accordingly the structure of the recombinant Che a 2 was altered to generate a hypoallergenic variant (rChe a 2.rs). Moreover, TD epitope was incorporated to produce a novel vaccine that was nominated as rChe a 2.rs^T.D. The effect of treatment with these variants was evaluated on the generation of allergen-specific IgG class, as well as lymphocyte proliferation in mice. Moreover, IgE-binding characteristics of the allergic patients' sera were determined by ELISA and proliferation and cytokine production was measured in T-cells.RESULTSELISA and dot blot revealed strong reduction of the IgE-reactivity of human sera to the variants of Che a 2 as compared to the wild-type molecule. Furthermore, Che a 2.rs and Che a 2.rs^T.D induced much lower levels of IL5 and IL13 secretion from allergic patients' PBMCs in comparison to wild-type Che a 2 protein. In mice, rChe a 2.rs^T.D induced high titers of Che a 2-specific IgG antibody capable of blocking IgE-binding to rChe a 2 and induced lymphocyte proliferation more potently than rChe a 2.rs.CONCLUSIONCollectively, incorporation of T-cell epitopes of tetanus and diphtheria into hypoallergenic vaccines can dramatically enhance anti-allergic immune mechanisms, particularly in poor responders.

100 Deals associated with Grass pollen allergy immunotherapy(BIAL-Portela & Cia SA)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB10394

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Rhinitis, Allergic, Seasonal	Phase 2	DE	ROXALL Medizin GmbH	26 Jan 2021
Allergic rhinoconjunctivitis	Phase 2	PT	BIAL-Portela & Cia SA	-
Allergic rhinoconjunctivitis	Phase 2	PT	BIAL-Portela & Cia SA	-
Conjunctivitis, Allergic	Phase 2	-	BIAL-Portela & Cia SA	-
Conjunctivitis, Allergic	Phase 2	-	BIAL-Portela & Cia SA	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01567306 (CTgov)	Phase 2	Rhinoconjunctivitis \| Asthma \| Rhinitis, Allergic	151	Allergovac Depot (Allergovac Depot Group 1 Active)	qxcxkpbywt(epqbklvqqa) = scbijlarvy kqtbqpskog (nugxvbstrz, wvrnvwsyfy - yllljifyxe) View more	-	29 Apr 2019
				Allergovac Depot (Allergovac Depot Group 2 Active)	qxcxkpbywt(epqbklvqqa) = evskrazwmp kqtbqpskog (nugxvbstrz, egkefynixr - ggpjsiapfp) View more